Quoin Pharmaceuticals, Ltd.
As of Oct 22, 2026, Quoin Pharmaceuticals is in Stage 1, the basing phase, now in week 9 (since Aug 25, 2026). It closed at $4.01, 82.0% below its 52-week high and below its 200-day average, which is falling.
Quoin Pharmaceuticals, Ltd., a late-stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases in the United States. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is QNRX early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
QNRX among Biotechnology448th of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …448 | QNRX | Stage 1 · wk 9 | 13 | −40.6% |
Quoin Pharmaceuticals: quick answers
What stage is Quoin Pharmaceuticals in?
As of Oct 22, 2026, Quoin Pharmaceuticals (QNRX) is in Stage 1, the basing phase. It entered Stage 1 on Aug 25, 2026 and is in week 9. What the four stages mean
Is Quoin Pharmaceuticals in an uptrend?
Not yet. Quoin Pharmaceuticals is in Stage 1, a base that can come before an uptrend. It trades 36.3% below its 200-day average, which is falling.
How far is Quoin Pharmaceuticals from its 52-week high?
Quoin Pharmaceuticals closed at $4.01 on Oct 22, 2026, 82.0% below its 52-week high of $22.30. Its 52-week low is $3.25.
How has Quoin Pharmaceuticals performed over the past year?
As of Oct 22, 2026, Quoin Pharmaceuticals is down 75.2% over the past year and down 71.5% so far in 2026.
Which sector and industry is Quoin Pharmaceuticals in?
Quoin Pharmaceuticals is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
Quoin Pharmaceuticals, Ltd., a late-stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases in the United States. The company's lead product is QRX003, a topical lotion, which is in phase 2 to treat netherton syndrome (NS); phase 1 in to treat peeling skin syndrome; and in pre-clinical stage to treat SAM syndrome and ichthyosis. It also develops QRX008 for the treatment of scleroderma, which is in pre-clinical stage; and QRX009, to treat microcystic lymphatic malformations, venous malformations, angiofibroma, and other diseases. It has a research agreement with Queensland University of Technology. Quoin Pharmaceuticals, Ltd. was founded in 2018 and is based in Ashburn, Virginia. Quoin Pharmaceuticals, Ltd. is a subsidiary of Skinvisible, Inc.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.